Lou Marie Salomé Schleicher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lou Marie Salomé Schleicher has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ana Jagodic
Department of Family Medicine, Community Health Center Krapina, 49000 Krapina, Croatia
2 shared publications - Antea Krsek
Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia
2 shared publications - Lara Baticic
Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia
2 shared publications
Latest Publications
- Open Access
- 19 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9178
Nanomedicine-Driven Modulation of the Gut–Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer’s and Parkinson’s Disease
Chronic inflammation plays a crucial role in the pathogenesis and progression of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), where sustained neuroinflammatory responses contribute to neuronal damage and functional decline. Recent advances in nanomedicine offer novel therapeutic strategies aimed at modulating inflammation, with a focus on targeting the gut–brain axis, a key mediator in the interplay between systemic inflammation and neurodegeneration. Artificial intelligence (AI) has emerged as a transformative tool in this context, facilitating the integration of large, complex datasets to better understand the intricate relationship between gut microbiota dysbiosis, chronic neuroinflammation, the exposome (cumulative impact of lifelong environmental exposures), and disease manifestation. AI-driven approaches and integrating exposome data with AI enable deeper insights into exposure–microbiome–inflammation interactions, enhance our understanding of the inflammatory pathways involved, support the development of predictive models for disease progression, and optimize the delivery of nanomedicine-based therapeutics. Additionally, AI applications in neuroimaging and personalized therapy planning have shown promise in addressing both motor and non-motor symptoms. This review provides a comprehensive synthesis of current knowledge, highlighting the convergence of AI, nanomedicine, and chronic inflammation in neurodegenerative disease care.
- 19 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9178
Open AccessNanomedicine-Driven Modulation of the Gut–Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer’s and Parkinson’s Disease
Chronic inflammation plays a crucial role in the pathogenesis and progression of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), where sustained neuroinflammatory responses contribute to neuronal damage and functional decline. Recent advances in nanomedicine offer novel therapeutic strategies aimed at modulating inflammation, with a focus on targeting the gut–brain axis, a key mediator in the interplay between systemic inflammation and neurodegeneration. Artificial intelligence (AI) has emerged as a transformative tool in this context, facilitating the integration of large, complex datasets to better understand the intricate relationship between gut microbiota dysbiosis, chronic neuroinflammation, the exposome (cumulative impact of lifelong environmental exposures), and disease manifestation. AI-driven approaches and integrating exposome data with AI enable deeper insights into exposure–microbiome–inflammation interactions, enhance our understanding of the inflammatory pathways involved, support the development of predictive models for disease progression, and optimize the delivery of nanomedicine-based therapeutics. Additionally, AI applications in neuroimaging and personalized therapy planning have shown promise in addressing both motor and non-motor symptoms. This review provides a comprehensive synthesis of current knowledge, highlighting the convergence of AI, nanomedicine, and chronic inflammation in neurodegenerative disease care.
- Open Access
- 2 April 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (2) , 28
Microbiome Dysbiosis as a Driver of Neurodegeneration: Insights into Alzheimer’s and Parkinson’s Diseases
Microbiome dysbiosis—an imbalance in gut microbial communities—has emerged as a critical factor in the pathogenesis of neurological disorders, particularly Alzheimer’s and Parkinson’s diseases. This review examines the role of gut microbiota in neurodegeneration, emphasizing how dysbiosis disrupts gut–brain communication through mechanisms such as impaired gut permeability, systemic inflammation, and neuroinflammation. The gastrointestinal and central nervous systems interact bidirectionally, with microbial metabolites like short-chain fatty acids playing a pivotal role in maintaining gut and brain health. Dysbiotic shifts in microbial composition can compromise the blood–brain barrier, enabling inflammatory molecules to alter brain biochemistry and potentially accelerate neurodegenerative processes. Additionally, this review explores therapeutic strategies—including probiotics, prebiotics, and dietary modifications—designed to restore microbial balance, reduce neuroinflammation, and slow disease progression. Further research is essential to refine microbiome-targeted therapies and fully elucidate their potential in managing neurodegenerative diseases.
- 2 April 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (2) , 28
Open AccessMicrobiome Dysbiosis as a Driver of Neurodegeneration: Insights into Alzheimer’s and Parkinson’s Diseases
Microbiome dysbiosis—an imbalance in gut microbial communities—has emerged as a critical factor in the pathogenesis of neurological disorders, particularly Alzheimer’s and Parkinson’s diseases. This review examines the role of gut microbiota in neurodegeneration, emphasizing how dysbiosis disrupts gut–brain communication through mechanisms such as impaired gut permeability, systemic inflammation, and neuroinflammation. The gastrointestinal and central nervous systems interact bidirectionally, with microbial metabolites like short-chain fatty acids playing a pivotal role in maintaining gut and brain health. Dysbiotic shifts in microbial composition can compromise the blood–brain barrier, enabling inflammatory molecules to alter brain biochemistry and potentially accelerate neurodegenerative processes. Additionally, this review explores therapeutic strategies—including probiotics, prebiotics, and dietary modifications—designed to restore microbial balance, reduce neuroinflammation, and slow disease progression. Further research is essential to refine microbiome-targeted therapies and fully elucidate their potential in managing neurodegenerative diseases.